TY  - JOUR
AU  - Lorenzini, Luigi
AU  - Maranzano, Alessio
AU  - Ingala, Silvia
AU  - Collij, Lyduine E
AU  - Tranfa, Mario
AU  - Blennow, Kaj
AU  - Di Perri, Carol
AU  - Foley, Christopher
AU  - Fox, Nick C
AU  - Frisoni, Giovanni B
AU  - Haller, Sven
AU  - Martinez-Lage, Pablo
AU  - Mollison, Daisy
AU  - O'Brien, John
AU  - Payoux, Pierre
AU  - Ritchie, Craig
AU  - Scheltens, Philip
AU  - Schwarz, Adam J
AU  - Sudre, Carole H
AU  - Tijms, Betty M
AU  - Verde, Federico
AU  - Ticozzi, Nicola
AU  - Silani, Vincenzo
AU  - Visser, Pieter Jelle
AU  - Waldman, Adam
AU  - Wolz, Robin
AU  - Chételat, Gael
AU  - Ewers, Michael
AU  - Wink, Alle Meije
AU  - Mutsaerts, Henk
AU  - Gispert, Juan Domingo
AU  - Wardlaw, Joanna M
AU  - Barkhof, Frederik
TI  - Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.
JO  - Neurology
VL  - 103
IS  - 7
SN  - 0028-3878
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Ovid
M1  - DZNE-2024-01148
SP  - e209801
PY  - 2024
AB  - Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition.This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a 'cSVD severity' latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal).A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16
KW  - Humans
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: diagnostic imaging
KW  - Male
KW  - Female
KW  - Aged
KW  - Risk Factors
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Retrospective Studies
KW  - Cerebral Small Vessel Diseases: diagnostic imaging
KW  - Cerebral Small Vessel Diseases: complications
KW  - Cerebral Small Vessel Diseases: pathology
KW  - tau Proteins: cerebrospinal fluid
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Middle Aged
KW  - Magnetic Resonance Imaging
KW  - Biomarkers: cerebrospinal fluid
KW  - Brain: pathology
KW  - Brain: diagnostic imaging
KW  - Atrophy: pathology
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC11450612
C6  - pmid:39288341
DO  - DOI:10.1212/WNL.0000000000209801
UR  - https://pub.dzne.de/record/272157
ER  -